PLoS ONE (Apr 2008)

The CD81 partner EWI-2wint inhibits hepatitis C virus entry.

  • Vera Rocha-Perugini,
  • Claire Montpellier,
  • David Delgrange,
  • Czeslaw Wychowski,
  • François Helle,
  • André Pillez,
  • Hervé Drobecq,
  • François Le Naour,
  • Stéphanie Charrin,
  • Shoshana Levy,
  • Eric Rubinstein,
  • Jean Dubuisson,
  • Laurence Cocquerel

DOI
https://doi.org/10.1371/journal.pone.0001866
Journal volume & issue
Vol. 3, no. 4
p. e1866

Abstract

Read online

Two to three percent of the world's population is chronically infected with hepatitis C virus (HCV) and thus at risk of developing liver cancer. Although precise mechanisms regulating HCV entry into hepatic cells are still unknown, several cell surface proteins have been identified as entry factors for this virus. Among these molecules, the tetraspanin CD81 is essential for HCV entry. Here, we have identified a partner of CD81, EWI-2wint, which is expressed in several cell lines but not in hepatocytes. Ectopic expression of EWI-2wint in a hepatoma cell line susceptible to HCV infection blocked viral entry by inhibiting the interaction between the HCV envelope glycoproteins and CD81. This finding suggests that, in addition to the presence of specific entry factors in the hepatocytes, the lack of a specific inhibitor can contribute to the hepatotropism of HCV. This is the first example of a pathogen gaining entry into host cells that lack a specific inhibitory factor.